Joseph Catanzaro, Ph.D.

Joe Catanzaro is a director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in 2018, Catanzaro spent four years at Cowen, where he also covered biotechnology. Before making the move to Wall Street, Catanzaro worked as a research scientist at Stony Brook University in New York. His work there focused on oncogene-mediated inflammatory signaling and resulted in multiple peer-reviewed publications. Catanzaro received his bachelor’s degree from Binghamton University in biological sciences and earned his Ph.D. in genetics from Stony Brook University.

Universe Coverage

Biotechnology
AADI	Aadi Bioscience, Inc.
ACHL	Achilles Therapeutics, Inc.
ACRV	Acrivon Therapeutics, Inc.
BMEA	Biomea Fusion, Inc.
BDTX	Black Diamond Therapeutics, Inc.
BOLD	Boundless Bio Inc.
CRDF	Cardiff Oncology, Inc.
CPRX	Catalyst Pharmaceuticals, Inc.
CNTX	Context Therapeutics, Inc.
CTMX	CytomX Therapeutics, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
EPIX	ESSA Pharma, Inc.
EXEL	Exelixis, Inc.
GILD	Gilead Sciences, Inc.
HALO	Halozyme Therapeutics, Inc.
IMAB	I-Mab
IMTX	Immatics NV
IBRX	ImmunityBio, Inc.
IOVA	Iovance Biotherapeutics, Inc.
KROS	Keros Therapeutics, Inc.
LPTX	Leap Therapeutics, Inc.
LENZ	LENZ Therapeutics, Inc.
NRIX	Nurix Therapeutics, Inc.
RPTX	Repare Therapeutics Inc.
RVMD	Revolution Medicines, Inc.
SDGR	Schrodinger, Inc.
TNGX	Tango Therapeutics, Inc.
TSBX	Turnstone Biologics Corp.